|
|
|
21.05.25 - 22:33
|
Cellectis′ Annual Shareholders General Meeting to be Held on June 26, 2025 (GlobeNewswire EN)
|
|
|
NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 26, 2025 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France....
|
|
|
|
|
12.05.25 - 22:33
|
Cellectis Reports Financial Results for the First Quarter 2025 (GlobeNewswire EN)
|
|
|
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided financial results for the first quarter 2025, ending March 31, 2025, and provided a business update....
|
|
|
|
|
06.05.25 - 22:33
|
Cellectis to Report First Quarter Financial Results on May 12, 2025 (GlobeNewswire EN)
|
|
|
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2025 ending March 31, 2025 on Monday, May 12, 2025 after the close of the US market....
|
|
|
28.04.25 - 22:33
|
Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting (GlobeNewswire EN)
|
|
|
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today unveils research data on TALEN®-mediated non-viral transgene insertion for advancing cellular and gene therapies, and advancements in genetic editing using TALE base editors (TALEB), at the Society of Gene and Cell Therapy (ASGCT) annual meeting, that will be held on May 13-17, 2025 in New Orleans....
|
|
|
|
|
|
|
07.03.25 - 22:33
|
Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025 (GlobeNewswire EN)
|
|
|
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2024 ending December 31, 2024 on Thursday, March 13, 2025 after the close of the US market....
|
|
|
24.02.25 - 07:33
|
Cellectis Presents ′Smart CAR T′ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 (GlobeNewswire EN)
|
|
|
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, showcases an innovative strategy for T cell engineering that leverages the pro-inflammatory properties of interleukin 2 (IL-2) with the objective to enhance CAR T cell efficacy against solid tumors, at the American Association for Cancer Research – Immuno-oncology (AACR-IO), taking place on February 23-26, 2025 in Los Angeles, CA....
|
|
|
|
|
|
|
10.12.24 - 22:33
|
Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB) (GlobeNewswire EN)
|
|
|
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it has drawn down the final tranche of €5 million (“Tranche C”) under the credit facility agreement for up to €40 million entered into with the European Investment Bank (the “EIB) on December 28, 2022 (the "Finance Contract"). With the drawdown of Tranche C, the Company has drawn down the full €40 million available under the Finance Contract. Tranche C is expected to be disbursed by the EIB by December 18, 2024. The Company plans to use the proceeds of Tranche C towards the development of its pipeline of allogeneic CAR T-cell product candidates: UCART22 and UCART20x22....
|
|
|
05.11.24 - 22:33
|
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting (GlobeNewswire EN)
|
|
|
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical data to enhance CAR T cell activity against solid tumors while preventing potential toxicity, will be presented at the Society for Immunotherapy of Cancer's 39th Annual Meeting (SITC), that will take place on November 6-10, 2024 in Houston, Texas....
|
|
|
|
|
|
|
30.10.24 - 21:36
|
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024 (GlobeNewswire EN)
|
|
|
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter 2024 ending September 30, 2024 on Monday, November 4, 2024 after the close of the US market....
|
|
|
22.10.24 - 08:06
|
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress (GlobeNewswire EN)
|
|
|
NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that they will be showcasing pre-clinical data that permit the design of an efficient and specific TALE base editors (TALEB) as well as a process to enhance the efficacy of non-viral gene insertion in hematopoietic stem and progenitor cells (HSPCs) at the European Society of Cell and Gene Therapy 31st annual congress, that will take place on October 22-25, 2024, in Roma, Italy....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
